Search results
Showing 2131 to 2145 of 2548 results for methods
Serelaxin for the treatment of acute decompensated heart failure [ID673]
Discontinued Reference number: GID-TAG454
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development Reference number: GID-TA10489 Expected publication date: TBC
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
Discontinued Reference number: GID-MT517
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
In development Reference number: GID-TA10745 Expected publication date: 17 July 2024
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Discontinued Reference number: GID-TA10134
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151
Discontinued Reference number: GID-TA10154
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued Reference number: GID-TA10212
Discontinued Reference number: GID-TA10425
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued Reference number: GID-TA10570
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued Reference number: GID-TA10609